论文部分内容阅读
目的:探讨聚乙二醇干扰素α-2a联合利巴韦林及双环醇治疗慢性丙型肝炎(慢性丙肝)的临床效果。方法:按照数字随机分组法将50例基因1型慢性丙肝患者随机分为实验组和对照组,实验组给予聚乙二醇干扰素α-2a联合利巴韦林、双环醇治疗,对照组给予聚乙二醇干扰素α-2a联合利巴韦林治疗,比较两组治疗期间肝功能改善状况、丙型肝炎病毒应答率以及不良反应发生情况。结果:治疗后第4、12、24周肝功能[总胆红素(TBIL)、谷丙转氨酶(ALT)、谷草转氨酶(AST)]复常率实验组均明显优于对照组,差异均有统计学意义(P<0.05)。两组HCV RNA应答率比较,快速病毒学应答(RVR)、早期病毒学应答(EVR)、完全早期病毒学应答(e EVR)、持续病毒应答率(SVR)实验组明显优于对照组36%vs.8%、80%vs.52%、68%vs.40%,差异均有统计学意义(P<0.05)。治疗期间两组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论:在聚乙二醇干扰素α-2a联合利巴韦林治疗基础上加用双环醇治疗慢性丙肝,可明显改善患者肝功能、提高丙型肝炎病毒应答率。
Objective: To investigate the clinical effect of peginterferon alfa-2a combined with ribavirin and bicyclol in the treatment of chronic hepatitis C (chronic hepatitis C). Methods: Fifty patients with genotype 1 chronic hepatitis C were randomly divided into experimental group and control group according to the method of digital randomization. The experimental group was treated with pegylated interferon alfa-2a combined with ribavirin and bicyclol and the control group Peginterferon alfa-2a combined with ribavirin treatment, two groups during treatment to improve the liver function, hepatitis C virus response rate and adverse reactions. Results: The normalization rates of liver function (total bilirubin, ALT and AST) in the 4th, 12th and 24th week after treatment were significantly better than those in the control group Statistical significance (P <0.05). The response rate of HCV RNA between the two groups was significantly higher than 36% of the control group in the experimental group of rapid virological response (RVR), early virological response (EVR), complete early virological response (e EVR) and continuous virus response rate (SVR) vs.8%, 80% vs.52%, 68% vs.40%, the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P> 0.05). Conclusion: The addition of bicyclol to chronic hepatitis C on the basis of peginterferon alfa-2a plus ribavirin can significantly improve the liver function and improve the response rate of hepatitis C virus.